Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
GAITHERSBURG, Md., Sept. 20, 2017 -- OpGen, Inc. (NASDAQ:OPGN) today announced that Evan Jones, the Company’s Chairman and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017 at 4:00 p.m. Eastern time. The conference is being held that day at the Sofitel Hotel in New York City.
To listen to the presentation live, investors may visit the investor relations section of OpGen, Inc.’s website at www.opgen.com. An archived webcast of the presentation will also be available on OpGen’s website for a time.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. For more information, please visit www.opgen.com.
OpGen®, Acuitas®, Acuitas Lighthouse® and QuickFISH® are registered trademarks of OpGen, Inc.
OpGen Contact:
Michael Farmer
Sr. Director, Marketing
240-813-1284
[email protected]
[email protected]
Investor Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
[email protected]
or
Bruce Voss
310-691-7100
[email protected]
